In non‐small cell lung cancer cells, Amentoflavone treatment significantly increases the cell population at the G1/G0 phase by decreasing the expression of cyclin D1, CDK4, and CDK6 in both H358 and H1299 cells.31 Here, CDK4 is linked to lung cancer.